Videos

An implantable cardioverter defibrillator (ICD) and its associated leads viewed on a X-ray. Old leads are often abandon in veins and new ones added, but a new study of 1 million patients at ACC22 showed there is higher mortality if a device becomes infected and the leads are left behind. Image from RSNA.

VIDEO: Lowering mortality rates from infected EP implantable cardiac devices

Sean Pokorney, MD, director of the arrhythmia core lab, Duke Clinical Research Institute, assistant professor of Medicine, Duke University, discusses a late-breaking ACC 2022 study that shows mortality is higher in patients with implantable electrophysiology (EP) device infections where the leads are not explanted.

A late-breaking study at ACC.22 showed differences in COVID-positive heart attack patients between 2020 and 2021. #ACC22 #ACC2022

VIDEO: Vaccines boosted survival among STEMI heart attack patients with COVID-19

Santiago Garcia, MD, lead author of the study and director of the structural heart program at The Christ Hospital in Cincinnati, Ohio, presented new data from the North American COVID-19 STEMI (NACMI) registry at ACC.22. Severity of heart attacks were reduced in vaccinated patients, with zero deaths in vaccinated patients in 2021.

VIDEO: 4 predictions on key cardiac technologies for the coming years

Mass General cardiologist and Harvard professor Ami Bhatt, MD, predicts upcoming paradigm shifts in cardiology over the next decade. 

A cardiac CT scan being performed on a Cardiograph dedicated cardiac CT scanner at a Duly Health and Care outpatient clinic. Photo by Dave Fornell

VIDEO: Office-based cardiac CT and FFR-CT offer a new business model

In a new video, Evans Pap­pas, MD, and Sujith Kalathiveetil, MD, both of Duly Health and Care in suburban Chicago, explain the shift toward office-based cardiac CT evaluations and the role of FFR-CT. 

Ami Bhatt, MD, the American College of Cardiology (ACC) Chief Innovation Officer, and an Adult Congenital Heart Disease cardiologist at Mass General Hospital (MGH). She is viewed one of the national experts on telecardiology, having been the former director of telecardiology at Mass General during 2020-2021.

VIDEO: American College of Cardiology working to propel cardiovascular innovation

Ami Bhatt, MD, explained how the ACC is working to advance new technologies that can improve patient care.

Stacey Wolfson, MD, chief resident, and Beatriu Reig, MD, MPH, clinical assistant professor of radiology, Department of Radiology, NYU Grossman School of Medicine, explain the findings of a study they were the lead authors on published in Radiology. Their study looked at 1,200 women who were vaccinated and received breast imaging exams, and they found several cancers, so their conclusion is not to wait for breast imaging after receiving a COVID vaccine or booster.

VIDEO: Should women wait to get mammograms after COVID vaccination?

In an exclusive video, Stacey Wolfson, MD, and Beatriu Reig, MD, MPH, from the NYU Grossman School of Medicine, discuss the findings of their new analysis. 

Thumbnail

Brent Lang, CEO, Vocera

Brent Lang, CEO of Vocera at HIMSS17 saw the discussions focused on security, interoperability, and resiliency. Now and into the future, mobile technology will be the key enabler to improving the patient experience.

Thumbnail

Don Woodlock, GM, Enterprise Imaging, GE Healthcare IT

Don Woodlock, GM of Enterprise Imaging at GE Healthcare IT discusses at HIMSS17 the importance of creating a more holistic view of the patient for the provider. The best way to accomplish this task is to integrate all specialties, images, test results into one EMR, allowing a complete view of patient information.

Around the web

These companies were already part of the Johnson & Johnson family, but they had still retained their previous brand names. Now, each one is officially going by Johnson & Johnson MedTech. 

The sensors of certain FreeStyle Libre 3 devices are producing inaccurate glucose readings and should not be used. Two patient injuries have been reported. Abbott first reported the problem in July. 

Medications that target obesity are not typically covered by Medicare. When the FDA approved semaglutide as a way to treat certain cardiovascular risks, however, CMS said Medicare coverage was on the table. 

Trimed Popup
Trimed Popup